A Study to Evaluate the Effects of Phenytoin and Itraconazole on Sonrotoclax (BGB-11417) in Healthy Volunteers

Inclusion Criteria: * Able to understand and sign a written informed consent * Able and willing to comply with all study requirements * Healthy males or healthy females of non-childbearing potential * Agrees to use an adequate method of contraception * Body mass index (BMI) of 18.0 to 32.0 kg/m\^2 as measured at screening or, if outside the range, considered not clinically significant by the investigator. Exclusion Criteria: * Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), or human immunodeficiency (HIV) antibody results * Prior treatment with sonrotoclax * Evidence of renal impairment at screening * Any contraindication to the use of phenytoin (Part A) or itraconazole (Part B) * Current smokers and those who have smoked within the last 12 months * Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months * History of any drug or alcohol abuse in the past 2 years * Serious adverse reaction or serious hypersensitivity to any drug or formulation excipients * History of clinically significant disorders as judged by the investigator Note: Other protocol defined Inclusion/Exclusion criteria may apply.